Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Chimeric Therapeutics Ltd. ( (AU:CHM) ) just unveiled an announcement.
Chimeric Therapeutics Ltd. announced an upcoming webinar featuring Professor Jennifer Eads, the Principal Investigator of its CHM CDH17 Phase 1/2 clinical trial, to discuss the company’s first-in-class CAR T therapy for gastrointestinal and neuroendocrine tumors. This event highlights Chimeric’s commitment to advancing its innovative cell therapy pipeline and may strengthen its position in the oncology market by showcasing its pioneering research and development efforts.
More about Chimeric Therapeutics Ltd.
Chimeric Therapeutics Ltd. is a clinical-stage cell therapy company focused on developing innovative cell therapies for cancer treatment. The company is advancing a pipeline of novel CAR T cell therapies and has a diversified portfolio that includes autologous CAR T cell therapies and allogeneic NK cell therapies, with assets being developed across multiple oncology disease areas.
Technical Sentiment Signal: Sell
Current Market Cap: A$9.76M
For detailed information about CHM stock, go to TipRanks’ Stock Analysis page.